Ledyard National Bank Sells 334 Shares of Hologic, Inc. (NASDAQ:HOLX)

Ledyard National Bank trimmed its holdings in Hologic, Inc. (NASDAQ:HOLX) by 4.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,681 shares of the medical equipment provider’s stock after selling 334 shares during the quarter. Ledyard National Bank’s holdings in Hologic were worth $554,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Wolff Wiese Magana LLC purchased a new stake in Hologic in the third quarter worth $25,000. General Partner Inc. bought a new position in shares of Hologic in the fourth quarter worth about $26,000. Groupama Asset Managment increased its stake in Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 2,999 shares during the period. First Horizon Advisors Inc. increased its stake in Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 134 shares during the period. Finally, Cromwell Holdings LLC lifted its holdings in Hologic by 330.2% during the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 416 shares in the last quarter. 94.73% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on HOLX shares. Evercore ISI dropped their target price on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a research note on Thursday. JPMorgan Chase & Co. raised their price objective on Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Mizuho cut their price target on Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 5th. Finally, UBS Group lifted their price objective on Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Ten investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $85.77.

Hologic Trading Down 10.1 %

NASDAQ:HOLX opened at $65.45 on Friday. The stock has a market capitalization of $14.77 billion, a price-to-earnings ratio of 19.65, a PEG ratio of 2.35 and a beta of 0.98. Hologic, Inc. has a 52 week low of $64.87 and a 52 week high of $84.67. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The firm has a 50 day moving average of $72.63 and a 200 day moving average of $77.86.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. As a group, sell-side analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 1.88% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.